79 related articles for article (PubMed ID: 18595702)
1. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
Torrisi R; Dellapasqua S; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Peruzzotti G; Rocca A; Balduzzi A; Cardillo A; Goldhirsch A; Colleoni M
Breast; 2008 Dec; 17(6):654-60. PubMed ID: 18595702
[TBL] [Abstract][Full Text] [Related]
2. Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer.
Torrisi R; Colleoni M; Veronesi P; Rocca A; Peruzzotti G; Severi G; Medici M; Renne G; Intra M; Luini A; Nolè F; Viale G; Goldhirsch A
Breast; 2007 Feb; 16(1):73-80. PubMed ID: 16908152
[TBL] [Abstract][Full Text] [Related]
3. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
D'Alessandro C; Dellapasqua S; Orlando L; Santoro L; Maisonneuve P; Torrisi R; Balduzzi A; Scarano E; Ghisini R; Peruzzotti G; Goldhirsch A; Colleoni M
Breast J; 2008; 14(5):435-41. PubMed ID: 18821931
[TBL] [Abstract][Full Text] [Related]
4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
6. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Chow LW; Yip AY; Loo WT; Toi M
Cancer Lett; 2008 Apr; 262(2):232-8. PubMed ID: 18248884
[TBL] [Abstract][Full Text] [Related]
9. Preoperative (neoadjuvant) systemic treatment of breast cancer.
Kaufmann M; von Minckwitz G; Rody A
Breast; 2005 Dec; 14(6):576-81. PubMed ID: 16199160
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
12. Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study.
Bollet MA; Sigal-Zafrani B; Gambotti L; Extra JM; Meunier M; Nos C; Dendale R; Campana F; Kirova YM; Diéras V; Fourquet A;
Eur J Cancer; 2006 Sep; 42(14):2286-95. PubMed ID: 16893641
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].
Straver ME; van Adrichem JC; Rutgers EJ; Rodenhuis S; Linn SC; Loo CE; Gilhuijs KG; Oldenburg HS; Wesseling J; Russell NS; Antonini N; Vrancken Peeters MT
Ned Tijdschr Geneeskd; 2008 Nov; 152(46):2519-25. PubMed ID: 19055260
[TBL] [Abstract][Full Text] [Related]
14. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase.
Colleoni M; Curigliano G; Minchella I; Peruzzotti G; Nolè F; Mazzarol G; Renne G; Orlando L; Rocca A; Veronesi P; Intra M; Viale G; Sandri MT; Severi G; Goldhirsch A
Ann Oncol; 2003 Oct; 14(10):1477-83. PubMed ID: 14504046
[TBL] [Abstract][Full Text] [Related]
15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
16. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
18. [Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
Zhang B
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):877-80. PubMed ID: 19173839
[No Abstract] [Full Text] [Related]
19. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
Nolè F; Minchella I; Colleoni M; Orvieto E; Munzone E; de Braud F; Peruzzotti G; Martinelli G; Zampino MG; Catania C; Pizzamiglio M; Veronesi P; Zurrida S; Galimberti V; Goldhirsch A; Veronesi U
Ann Oncol; 1999 Aug; 10(8):993-6. PubMed ID: 10509165
[TBL] [Abstract][Full Text] [Related]
20. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Torrisi R; Bagnardi V; Cardillo A; Bertolini F; Scarano E; Orlando L; Mancuso P; Luini A; Calleri A; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2008 Nov; 99(10):1564-71. PubMed ID: 18941458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
